60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
60 Degrees Pharma reports DSMB recommends continuing the B-FREE Phase 2 chronic babesiosis study after finding no safety concerns.
60 Degrees Pharma reports DSMB recommends continuing the B-FREE Phase 2 chronic babesiosis study after finding no safety concerns.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.